Eli Lily’s profits doubled in the fourth quarter, causing her hot sale Treatment of diabetes and obesityAnd the drug maker came out with more expected predictions than 2025.
Lily’s highest sales products, diabetes treatment moonjaro, increased by 60 % in the last quarter of 2024 to $ 3.53 billion, while his obesity was brought to $ 1.9 billion to the zipbound.
Breast cancer treatment also helped revenue, which increased from 36 % to $ 1.55 billion.
Overall, Lily’s quarterly profit reached $ 41.41 billion. As expected, revenue increased by 45 %, reached $ 13.53 billion. According to a survey of industry analysts through the Fact Set, the Wall Street looking for Wall Street, the time -to -share income per share for one -time items is $ 5.32.
Moujaro and Zipbound are a part of diabetes and obesity pharmaceuticals, known as the GLP-1 receptor Egonists, which are increasing global popularity due to loss of weight while injection. They do the competition Ozampk and Vigovo Danish drug drugmaker Novo Nordesk, who also reported a tremendous increase in sales on Wednesday.
For 2024, the sales of Moonjaro doubled to $ 11.54 billion, while Zipbound sold 9 4.9 billion in the market in its first year.
Analysts have expected more than $ 18 billion from Moonjaro this year and more than $ 10 billion from the Zipbound, which was recently approved as a treatment for some forms of sleep deprivation in the United States.
For 2025, Indianapolis drug makers expect the adjusted income between $ 22.50 to 24 and revenue will be reduced between $ 58 billion to $ 61 billion.
Analysts expect revenue of $ 58.8 billion .82.77 per share income.
Eli Lily and the company’s shares fell to $ 831.64 in the premier trading on Thursday. By Wednesday this year, the stock had already risen to 9 %.
